Victory Capital Management Inc. lowered its position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) by 39.9% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 800,472 shares of the biopharmaceutical company’s stock after selling 531,570 shares during the period. Victory Capital Management Inc. owned 3.06% of Loxo Oncology worth $64,189,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in LOXO. Aisling Capital LLC boosted its stake in Loxo Oncology by 4.0% in the first quarter. Aisling Capital LLC now owns 4,188,920 shares of the biopharmaceutical company’s stock worth $176,270,000 after buying an additional 160,000 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in Loxo Oncology by 41.5% in the first quarter. Driehaus Capital Management LLC now owns 598,863 shares of the biopharmaceutical company’s stock worth $25,200,000 after buying an additional 175,587 shares in the last quarter. Swiss National Bank boosted its stake in Loxo Oncology by 53.5% in the first quarter. Swiss National Bank now owns 28,700 shares of the biopharmaceutical company’s stock worth $1,208,000 after buying an additional 10,000 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Loxo Oncology by 41.8% in the first quarter. Bank of New York Mellon Corp now owns 102,442 shares of the biopharmaceutical company’s stock worth $4,310,000 after buying an additional 30,210 shares in the last quarter. Finally, Foresite Capital Management III LLC acquired a new stake in Loxo Oncology during the first quarter worth $4,208,000.

Loxo Oncology, Inc. (NASDAQ:LOXO) opened at 74.19 on Friday. Loxo Oncology, Inc. has a 12 month low of $17.14 and a 12 month high of $83.12. The firm has a 50-day moving average price of $73.71 and a 200-day moving average price of $57.32. The company’s market capitalization is $2.21 billion.

Loxo Oncology (NASDAQ:LOXO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by $0.15. During the same period in the prior year, the firm posted ($0.77) EPS. On average, equities analysts anticipate that Loxo Oncology, Inc. will post ($4.53) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/27/loxo-oncology-inc-loxo-position-cut-by-victory-capital-management-inc.html.

LOXO has been the subject of a number of recent analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $91.00 price target on shares of Loxo Oncology in a report on Monday, June 19th. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a report on Thursday, June 8th. Ifs Securities reaffirmed an “outperform” rating on shares of Loxo Oncology in a report on Tuesday, August 8th. Stifel Nicolaus increased their price objective on Loxo Oncology from $52.00 to $71.00 and gave the company a “buy” rating in a research report on Monday, June 5th. Finally, Citigroup Inc. upgraded Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 price objective on the stock in a research report on Monday, June 5th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $79.67.

In related news, Director Keith T. Flaherty sold 7,250 shares of Loxo Oncology stock in a transaction on Monday, August 21st. The shares were sold at an average price of $72.26, for a total value of $523,885.00. Following the transaction, the director now owns 20,432 shares in the company, valued at approximately $1,476,416.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lori Anne Kunkel sold 10,000 shares of Loxo Oncology stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $75.17, for a total transaction of $751,700.00. Following the completion of the transaction, the director now owns 16,840 shares in the company, valued at approximately $1,265,862.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,073 shares of company stock worth $3,397,662. 44.40% of the stock is owned by corporate insiders.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.